Telomir Pharmaceuticals, Inc. 8-K

What Happened
Telomir Pharmaceuticals, Inc. announced in an 8‑K that on March 30, 2026 it received a letter from Nasdaq Capital Markets stating that, after the company held its 2025 Annual Meeting of Shareholders, Telomir is now in compliance with Nasdaq Listing Rule 5620(a). Nasdaq has determined the matter closed.

Key Details

• Letter received from Nasdaq Capital Markets on March 30, 2026.
• Compliance relates specifically to Nasdaq Listing Rule 5620(a).
• Nasdaq confirmed compliance followed the company’s 2025 Annual Meeting of Shareholders.
• Nasdaq has determined the matter closed (no further action noted in the filing).

Why It Matters
This resolves a Nasdaq listing compliance issue tied to Rule 5620(a), removing a regulatory deficiency that could have posed a risk to the company’s continued listing. For investors, the filing indicates Telomir has satisfied Nasdaq’s requirement tied to its 2025 shareholder meeting; the 8‑K does not report any financial results, management changes, or other material events.